MOESM4 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Additional file 4: Figure S4. Forest plot of the long-term prognostic outcomes of anti-PD-1/PD-L1 monotherapy in other cancer (Non-smoker vs. Smoker), PNon-smoker=0.094, PSmoker=0.001.